Using nasal delivery of specific peptides to treat Alzheimer's disease
Intranasal delivery of VGF-derived peptides in a preclinical model of Alzheimer's disease
This study is looking at whether a special treatment delivered through the nose can help improve thinking and memory in people with Alzheimer's by reducing harmful brain deposits.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11103164 on NIH RePORTER |
What this research studies
This research investigates the potential of delivering VGF-derived peptides through the nasal route to improve cognitive function in Alzheimer's disease. By focusing on a preclinical model, the study aims to understand how these peptides can reduce amyloid deposition and cognitive impairment associated with Alzheimer's. The approach involves optimizing the delivery method to ensure effective absorption into the brain, leveraging the unique properties of the peptides to activate specific receptors involved in neuroprotection and cognitive enhancement.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with late-onset Alzheimer's disease who may benefit from innovative treatment approaches.
Not a fit: Patients with early-onset Alzheimer's disease or those with other forms of dementia may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options that significantly improve cognitive function and slow the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promise in using similar peptide-based approaches for neuroprotection in Alzheimer's models, indicating potential for success in this novel application.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Salton, Stephen R — Icahn School of Medicine at Mount Sinai
- Study coordinator: Salton, Stephen R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.